top of page

Mass cytometry papers in COVID from 2020

You will find the list of papers of mass cytometry (CyTOF) investigating COVID-19 in 2020.


We also propose two other reviews, one about mass cytometry data in blood cancers, the other in solid tumors. 


Dario Bongiovanni


8 patients 11 donors

Number of markers

21 markers

Investigation of transmembrane proteins in platelets of hospitalized COVID-19 patients. Non-stimulated platelets compared to stimulated platelets. In COVID patients, significantly reduced capacity of platelets to increase the expression of activation markers LAMP-3 and P-Selectin upon stimulation with TRAP.

SARS-CoV-2 infection is associated with a pro-thrombotic platelet phenotype

Cell Death & Disease


Wen Shi


5 healthy donors 9 COVID patients

Number of markers

29 markers

Comparison of peripheral blood between HD and COVID patients and identification of CD4 depletion.

High-dimensional single-cell analysis reveals the immune characteristics of COVID-19

Lung cellular and molecular physiology


Jason Neidleman


9 COVID19 (mild, recovered)

Number of markers

38 markers

Characterisation of T cells from COVID19 recovered patients. SARS-CoV-2-specific CD4+ T cells were exclusively Th1 cells (predominantly Tcm). SARS-CoV-2-
specific CD8+ T cells were predominantly TemRA cells (in less terminal differentiation state). Subsets of SARS-CoV-2-specific T cells express CD127, can homeostatically proliferate, and can persist for over two months.

SARS-CoV-2-specific T cells exhibit phenotypic features of robust helper function,
lack of terminal differentiation, and high proliferative potential

Cell Reports Medicine


Tal Goshen-Lago


164 cancer patients and 107 healthcare workers

Number of markers

39 markers

Due to differential immune cell profile of cancer patients who are treated with immunomodulatory agents, the host response to the SARS-COV2 may lessen symptom severity.

The Potential Role of Immune Alteration in the Cancer–COVID19 Equation—A Prospective Longitudinal Study



Lucie Rodriguez


37 COVID19, and follow-up with 14 patients

Number of markers

48 markers

Characterisation of the immune response to COVID19 over time in the blood. IFNγ-eosinophil axis activated before lung hyperinflammation

Systems-Level Immunomonitoring from Acute to Recovery Phase of Severe COVID-19

Cell Reports Medicine


Prabhu S. Arunachalam


76 COVID-19 patients and 69 healthy individuals from Hong Kong and Atlanta

Number of markers

34 markers

Analysis of immune responses in between COVID-19 patients and healthy individuals from Hong Kong and Atlanta

Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans



Yingfeng Zheng


5+2 young healthy adults, 5+2 aged healthy adults, 2 young and 2 aged COVID19 patients

Number of markers

31 markers

Combined scRNA-seq, mass cytometry and scATAC-seq to compare immune cell types in peripheral blood collected from young and old subjects and patients with COVID-19

A human circulating immune cell landscape in aging and COVID-19

Protein& Cell


Jonas Schulte-Schrepping


40 COVID19, 8 Flu-like illness, 10 controls

Number of markers

55 markers in 2 panels

Integration of multiple platforms to study COVID19 over time showing:
- Mild COVID-19 corrolates with HLA-DRhiCD11chi CD14+ monocytes
- Severe COVID-19 corrolates with HLA-DRloCD163hi and HLA-DRloS100Ahi CD14+ monocytes

Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment


18 July 2020

Lindsey E. Padgett


30 convalescent patients with mild, moderate, and severe cases of COVID-19

Number of markers

41 markers

Mass cytometry to investigate peripheral myeloid cells and T lymphocytes from 30 convalescent patients with mild, moderate, and severe cases of COVID-19. CD14+CD16+ intermediate and CD14dimCD16+ nonclassical monocytes, as well as CD4+ stem cell memory T (TSCM) cells, correlated with COVID-19 severity. Both intermediate and non-classical monocyte subsets shape the adaptive immune response to SARS-CoV-2

Interplay of Monocytes and T Lymphocytes in COVID-19 Severity


13 July 2020

Jérôme Hadjadj


50 COVID-19 patients and 18 healthy controls

Number of markers

30 markers

Highly impaired IFN response (characterized by no IFN-β and low IFN-α production and activity) was found to be associated with a persistent blood viral load. Type-I IFN deficiency in blood could be a hallmark of severe COVID-19.

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients


29 June 2020

Daniel Geanon


19 COVID-19 patients

Number of markers

30 markers

Validation of a workflow for staining of whole blood samples with minimal processing requirements or expertise at the site of sample collection, followed by shipment to a central CyTOF core facility for batched downstream processing and data acquisition. Characterization of immune responses of COVID-19 patients, highlighting key disease-associated changes in immune cell frequency and phenotype.

A Streamlined CyTOF Workflow To Facilitate Standardized Multi-Site Immune Profiling of COVID-19 Patients


16 June 2020

Lin‐lin Wei


6 critical COVID‐19

Number of markers

33 markers

Mass cytometry to study COVID-19 patients. Good prognoses had significantly higher counts of monocytes, macrophages, higher frequency of CD3+CD4+CD45RO+CXCR3+ subsets, higher frequency of CD14+CD11C+HLA‐DR+ subset of dendritic cells and a lower count of neutrophils. Proportions of naïve CD4+ T cells, Tregs, and Th2 cells in the poor prognosis group were relatively higher than those in the good prognosis group, and CD4+ memory T cells were relatively lower.

Dysregulation of the immune response affects the outcome of critical COVID‐19 patients

Journal of Medical Virology

28 April 2020

Wenjing Wang


12 PBMCs from healthy donors and 12 from COVID-19 patients

Number of markers

36 markers

Mass cytometry profiled immune cellular components to analyze the peripheral blood mononuclear cells (PBMCs) from patients with differences in disease progression by comparing with the PBMCs from healthy donors (HDs).

High-dimensional immune profiling by mass cytometry revealed immunosuppression and dysfunction of immunity in COVID-19 patients

Cellular & Molecular Imunology


Number of markers


bottom of page